← Back to patent-cliff list
Neridronate Sodium
Tier C — Watch / tradeNeridronate Sodium
-
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bone resorption factor
Indications (approved)：成骨不全, Paget's disease
Regional status
US
-
EU
Approved
2002-01-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Neridronate Sodium?
Approved indications include: 成骨不全, Paget's disease.
When does the Neridronate Sodium patent expire?
No public expiry year is available for Neridronate Sodium yet; this page updates once verified.
How do I get a quote for Neridronate Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27